Email from Judy: | DNDNQ Message Board Posts

Dendreon Corporation

  DNDNQ website
  • Create your FREE account now  



    User Name:


    Password:


    Confirm Password:



    Email:



    I have read & agree to the InvestorVillage User Agreement.














    For assistance, call 888-222-7309.
  • TECH UPDATE: We are introducing some modest "Project Monkey" code changes tonight.  This update will include a new site setting where users will have the ability to set their own personal default font size for writing messages.  Over the course of the next few days, we will be explaining this change in greater detail for anyone who has questions about it. In the meantime, if you notice any glitches or unexpected changes to your normal site experience, please let us know as soon as possible.  You can send a PM to Admin or email admin@investorvillage.com or call us at 888-222-7309. Thanks!

DNDNQ   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  361096 of 478201  at  7/8/2010 3:29:10 PM  by

travfourr


Email from Judy:

From: Rightmire, Judy (jrightmire@Dendreon.com)
Sent: Thu 7/08/10 3:22 PM
To: JOE T4

Dear Joe –



We understand and appreciate your questions regarding PROVENGE and the reimbursement process we are currently undergoing. We appreciate that many people have questions about this process and hope to share as much information as we can to keep people better informed.



As you may know, PROVENGE is currently covered by some of the local Medicare Administrative Contractors (MACs) and private payers. Upon FDA approval, PROVENGE was given a generic J code, and we expect to receive a specific code when new J codes are scheduled to be administered in early 2012 (which is the case for any drug approved after March 31, 2010).



Last week, the Centers for Medicare and Medicaid Services (CMS) initiated a National Coverage Analysis (NCA). A NCA is generally a review of evidence to determine if the use of a product is reasonable and necessary. In CMS’ announcement of the NCA, CMS stated it is requesting public comments on the effects of PROVENGE on health outcomes in patients with prostate cancer. It is not a change in Medicare coverage policy.



What that means for physicians is that NCAs do not impact existing coverage decisions, nor do they restrict local Medicare contractors from covering PROVENGE. Therefore, Medicare beneficiaries are still able to access PROVENGE and private payers can also still cover PROVENGE.



We will work closely with CMS through this process. We appreciate your support.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 94     Views: 1821
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
361099 Re: Email from Judy: travfourr 53 7/8/2010 3:41:27 PM
361100 Re: Email from Judy: AMMASS 4 7/8/2010 3:43:53 PM
361219 Re: Email from Judy. - Worry, worry, worry about this. whyme? 25 7/8/2010 10:53:36 PM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2016 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...